Market research
QUCY Quantum Cyber N.V.
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 2.38
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- NL0015000LC2
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 2.38
About
About Quantum Cyber N.V.
Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions. The company pursues acquisitions and partnerships in areas including post-quantum cryptography, zero-trust architecture, and national security technologies. It also develops platforms that integrate artificial intelligence (AI) and quantum computing technologies for autonomous control systems used in unmanned aerial, ground, and underwater vehicles, including drones, self-driving vehicles, and robotic fleets. Quantum Cyber N.V. was formerly known as Mainz Biomed N.V. and changed its name to Quantum Cyber N.V. in April 2026. The company is headquartered in Mainz, Germany.
Research context
Quantum Cyber N.V. appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the QUCY discussion.
No comments yet
Start a focused discussion about QUCY.